Anti-Thrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (ATTACC-CAP )

 

ATTACC-CAP is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP). The trial will enroll patients in hospital emergency departments and wards prior to the onset of critical illness. It will recruit patients from ~ 70 sites across 4 countries with an anticipated sample size of 3000-4000 patients.

CAP is a life-threatening lung infection and a leading cause of hospitalization and mortality globally. Poor clinical outcomes are driven by maladaptive inflammatory and thrombotic host responses to infection, leading to micro- and macro-vascular thrombosis and organ dysfunction. In CAP caused by COVID-19, we demonstrated that therapeutic-dose anticoagulation with heparin reduced progression to organ failure and mortality in non-critically ill hospitalized patients. Whether heparin has a similar effect on other etiologies of CAP remains uncertain.

This trial is one of the first non-COVID CCCTG endorsed trials that aims to study a pre-ICU intervention for a life-threatening illness with the goal of preventing critical illness and improving outcomes.

For more information and a complete list of sites and investigators, visit our website: attacc.org